Immunic, Inc. (NASDAQ:IMUX) Receives $22.00 Consensus PT from Analysts
Immunic, Inc. (NASDAQ:IMUX – Get Rating) has received a consensus rating of “Moderate Buy” from the six brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating on the company. The average 1 […]